Peter Birk

MonTa Biosciences is a clinical stage biotech company located in the DTU science park in Kgs. Lyngby, Copenhagen. Our lead candidate MBS8 is a novel TLR7 agonist formulated in micelles, which show greater therapeutic activity and better safety profiles compared to non-formulated TLR7 agonists. We are currently running a phase I clinical study in solid tumor cancer patients at sites in Denmark, Belgium and Spain and have dosed more than 20 patients. MBS8 has the unique selling points: -MBS8 can turn “Cold” tumors into “Hot” tumors -Strong anti-tumor activity in a broad range of tumor models -Unique MoA based on Neutrophil activation and tumor cell killing -Can be administered intravenously -Show synergy with PD-1/PD-L1 checkpoint inhibitors Get in touch for more info

Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

Since 2008, Accelerace has supported 1000+ Danish and international startups, including Trustpilot and Templafy and have made 120+ pre-traction investments. Our aim to help as many startups succeed as possible - by investing, making our platform available for free and offer mentoring from other successful founders. In Accelerace we stand on the shoulders of everyone we have had come through, and we use that knowledge to pass on to the next generation of startups. Accelerace is also responsible for the management of NOME (Nordic Mentor Network for Entrepreneurship), an elite mentoring program for Nordic life science startups, and are partners on programmes: Beyond Beta, VITA and Beyond.

MonTa Biosciences is a clinical stage biotech company located in the DTU science park in Kgs. Lyngby, Copenhagen. Our lead candidate MBS8 is a novel TLR7 agonist formulated in micelles, which show greater therapeutic activity and better safety profiles compared to non-formulated TLR7 agonists. We are currently running a phase I clinical study in solid tumor cancer patients at sites in Denmark, Belgium and Spain and have dosed more than 20 patients. MBS8 has the unique selling points: -MBS8 can turn “Cold” tumors into “Hot” tumors -Strong anti-tumor activity in a broad range of tumor models -Unique MoA based on Neutrophil activation and tumor cell killing -Can be administered intravenously -Show synergy with PD-1/PD-L1 checkpoint inhibitors Get in touch for more info

Since 2008, Accelerace has supported 1000+ Danish and international startups, including Trustpilot and Templafy and have made 120+ pre-traction investments. Our aim to help as many startups succeed as possible - by investing, making our platform available for free and offer mentoring from other successful founders. In Accelerace we stand on the shoulders of everyone we have had come through, and we use that knowledge to pass on to the next generation of startups. Accelerace is also responsible for the management of NOME (Nordic Mentor Network for Entrepreneurship), an elite mentoring program for Nordic life science startups, and are partners on programmes: Beyond Beta, VITA and Beyond.

Nordic Mentor Network for Entrepreneurship (NOME) is an elite Nordic Mentoring program for promising life science projects and startups with world class mentors. NOME matches Nordic projects and startups with highly skilled volunteer professionals to help them reach their goals and technology milestones.

Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

Since 2008, Accelerace has supported 1000+ Danish and international startups, including Trustpilot and Templafy and have made 120+ pre-traction investments. Our aim to help as many startups succeed as possible - by investing, making our platform available for free and offer mentoring from other successful founders. In Accelerace we stand on the shoulders of everyone we have had come through, and we use that knowledge to pass on to the next generation of startups. Accelerace is also responsible for the management of NOME (Nordic Mentor Network for Entrepreneurship), an elite mentoring program for Nordic life science startups, and are partners on programmes: Beyond Beta, VITA and Beyond.